This medication is applied across domains where additional symptomatic support is needed, including anxiety and panic disorders. Berest is commonly used for short-term symptomatic assistance in conditions marked by increased discomfort or tension, such as Anxiety Disorder and Panic Disorder. Its primary purpose is to provide support that helps ease the overall symptom burden, contributing to improved comfort during challenging episodes.

Symptomatic Relief for Acute Manifestations

This medication helps address symptom clusters that may become intense or disruptive, such as the excessive worry and symptoms related to heightened physiological activity seen in acute anxiety, or the sudden, overwhelming episodes of panic. Berest is applied in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. It is relevant for easing symptoms and may assist patients with managing difficult and intensified episodes.

“Applied in contexts marked by increased discomfort or tension, this therapy may support patients during difficult episodes.”

Quick Fact: Symptomatic Support for Heightened Physiological Activity

Berest may assist with managing symptoms that interfere with daily comfort, and is often used during phases when symptoms become more noticeable and are linked to organ-specific functional stress.

Eligibility Map: Who can and cannot use Berest (Alprazolam) — official regulatory information

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults (18 years and older) for the FDA-indicated management of GAD and Panic Disorder.
Populations for whom use is not recommended	Pediatric patients (under 18 years); Nursing mothers; Pregnant women (due to risk of Neonatal Sedation and Withdrawal Syndrome).
Populations for whom use is contraindicated	Patients with known hypersensitivity to any benzodiazepine; Those taking strong CYP3A inhibitors (excluding ritonavir); Patients with acute narrow angle glaucoma.
Age-related eligibility rules	Safety and effectiveness have not been established for pediatric patients. Geriatric patients (≥ 65 years) require a lower initial starting dose.
Condition-specific eligibility rules	Use requires a lower initial dose in patients with hepatic impairment. Caution is required in patients with renal impairment or impaired respiratory function.

---

Connection to the overall eligibility profile

Official regulatory documents strictly define the eligibility profile by establishing absolute bars to use (contraindications), restricting use to the adult population, and mandating conditional use with a lower starting dose for specific vulnerable populations, such as the elderly or those with impaired liver function.

The official regulatory profile for Berest (Alprazolam) defines interactions across two primary domains: pharmacokinetic alteration and pharmacodynamic effects.

Contraindicated and High-Risk Combinations

Co-administration with potent CYP3A inhibitors, such as Ketoconazole and Itraconazole, is formally contraindicated in regulatory labeling. This prohibition is due to the potential for these agents to severely impair the drug's metabolism, significantly increasing plasma concentrations.

The concurrent use of Alprazolam and Opioids carries a formal boxed warning due to the risk of profound sedation, respiratory depression, coma, and death resulting from additive depressant effects on the central nervous system.

Pharmacokinetic and Pharmacodynamic Effects

Alprazolam is primarily cleared by the CYP3A enzyme system. Consequently, drugs that inhibit CYP3A (e.g., Fluvoxamine, Nefazodone) are expected to increase drug exposure, while CYP3A inducers (e.g., Carbamazepine) may decrease concentrations by accelerating clearance. Co-administration with Digoxin is documented to increase the risk of digoxin toxicity.

Due to the documented risk of enhanced CNS depression, the concomitant use of Alcohol or other CNS depressant drugs is advised against. Furthermore, clearance is intrinsically reduced, and half-life is prolonged, in populations with hepatic impairment and in elderly subjects, which heightens the risk of interaction-related exposure increases.

Positive Allosteric Modulation of GABAA Receptors

This mechanism focuses on GABAA receptors, the primary mediators of central nervous system (CNS) inhibition. The active ingredient in Berest binds to a distinct allosteric site on this receptor, which increases the effect of the body's natural neurotransmitter, GABA. This action leads to a heightened influx of chloride ions (Cl^-) into the neuron, promoting hyperpolarization and reduced action potential probability.

---

Modification of Central Inhibitory Pathways

Berest mediates changes in the activity within the GABAergic inhibitory pathway, particularly in brain regions such as the limbic system. By boosting the inhibitory tone of this pathway, the drug alters the balance of signaling patterns within specific CNS circuits, contributing to an overall increase in central inhibitory tone.

---

Direct Influence on Neuronal Excitability Threshold

The core mechanistic cascade modifies early molecular steps at the receptor level. This mechanism directly influences the neuronal excitability threshold, leading to a generalized depression of CNS function and predictable physiological consequences, including altered vigilance and reduced skeletal muscle tone, by limiting excessive neural firing.

Berest, identified by its active ingredient alprazolam, is administered exclusively via the oral route for all approved formulations. The medication is available as Immediate-Release (IR) tablets, Extended-Release (XR) tablets, Orally Disintegrating Tablets (ODT), and as an Oral Solution.

Dosing regimens are specific to the formulation and the treated condition. For the Immediate-Release tablets, the dosing schedule typically involves the total daily amount being administered in divided doses, often three times daily. In contrast, the Extended-Release tablets are used for once-daily administration. A key procedural instruction for the XR tablet is that it must be swallowed whole and is not to be crushed, chewed, or broken under any circumstances. IR tablets can generally be taken without regard to food.

The use of Berest is framed as a short-term intervention. The eventual discontinuation of the medication must follow a formal, gradual dose reduction, or tapering, protocol. Standard protocols indicate that the daily dosage should be decreased by no more than 0.5 mg every three days to ensure a controlled end to therapy. Furthermore, adjustments to the starting dose are specified for certain patient populations, with a lower initial dose required for older adults or individuals with severe hepatic impairment.

Recent Clinical Evidence

Research has explored whether clinical outcomes are affected in patients with moderately active Ulcerative Colitis (UC). The available evidence comes primarily from randomized controlled trials (RCTs) and subsequent meta-analyses. The findings center on the studies' primary and secondary endpoints, including measures of initial response, long-term outcomes, and safety profile across different patient groups.

---

Initial Response and Combination Therapy

The initial studies focused on evaluating the proportion of patients who met the endpoint criteria for clinical response or remission after 8 to 12 weeks of treatment with Berest.

• The studies reported that a higher percentage of patients receiving Berest met the definition of clinical remission compared to those receiving placebo.
• One study specifically investigated combined therapy with traditional aminosalicylates, which reported that patients receiving the combination had a finding of fewer clinical symptoms over a 12-month period. Further research is needed to determine whether this combination offers an advantage over monotherapy.

---

Long-term Maintenance

For patients who achieved initial response, studies examined Berest’s capacity to maintain clinical remission over a 52-week period. Data suggest that patients randomized to continued treatment with Berest was associated with a longer time in remission compared to those randomized to placebo or discontinuation.

---

Evaluation of Inflammation and Safety

Another meta-analysis evaluated Berest’s effect on biochemical markers of inflammation. The studies also evaluated whether the treatment is associated with earlier symptom changes in patients with severe disease activity.

Special Populations

Research has included elderly patients to evaluate the safety profile in this group. Available data from subgroup analyses and post-hoc studies showed comparable rates of adverse events in older adults compared to the general adult UC population.

Safety Profile Overview

The studies collected data on adverse events, including headache. The studies also included reported pain levels as a secondary endpoint for evaluation. This treatment is one approach explored in IBD management.

Common questions about Berest (FAQ)

---

Q: Is Berest safe to use long-term?

Clinical trials evaluating the medicine's efficacy were generally conducted over short periods, such as 4 to 10 weeks. According to the official product information, the risk of developing dependence and severe withdrawal reactions is known to increase with a longer duration of treatment and a higher daily dosage.

---

Q: Does Berest affect sleep?

Yes, official safety information indicates that the medicine can affect activity in the central nervous system. Common adverse reactions reflecting this effect are sedation and somnolence (drowsiness).

---

Q: Is Berest a controlled substance?

The active ingredient in Berest, alprazolam, is classified as a Schedule IV controlled substance by federal authorities. This classification is due to the potential for abuse and physical dependence.

---

Q: Can Berest be taken with or without food?

The official prescribing information states that the Immediate-Release (IR) tablets can generally be taken without regard to food. Official instructions for the Extended-Release (XR) tablets do not contain a specific food requirement.

---

Q: Does Berest lose its effectiveness over time?

While not directly stated, official warnings note that the risk of developing clinically significant physical dependence is linked to taking the medicine for a longer duration. Tolerance, meaning a reduced response to the drug’s effects, is a concept associated with medications of this type.

---

Q: What does Berest mean by 'contraindication'?

In medicine, a contraindication means there is a specific reason or situation where a medicine should not be used because the risk of harm outweighs any potential benefit. When a medicine is absolutely contraindicated, it means using it could cause a serious or life-threatening problem and must be strictly avoided.

---

Q: How quickly does Berest start working?

Studies indicate that after taking an oral tablet, the concentration of the active ingredient in the bloodstream typically reaches its peak within 1 to 2 hours. Clinical benefits for the condition it treats were established over longer periods, such as 4 to 10 weeks, in controlled trials.

---

Q: What happens if I miss a dose of Berest?

Regulatory patient instructions state that a missed dose is generally advised to be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guideline indicates that the missed dose is skipped entirely to prevent taking more than the prescribed amount at once.

---

Q: Are there any dietary restrictions while taking Berest?

Yes, regulatory documents advise patients to avoid consuming alcohol while taking the medicine. Alcohol can cause a dangerous increase in the central nervous system (CNS) depressant effects of the medicine.

---

Q: What should I do if I have an allergic reaction to Berest?

A known hypersensitivity to the medicine or to other benzodiazepines is an official contraindication, meaning the medicine is not recommended for use in this situation. In the event of a suspected severe allergic reaction, such as blistering or swelling, the official recommendation is to seek emergency medical attention.

---

Q: Does Berest interact with herbal supplements like St. John's Wort?

Official information indicates the active ingredient is broken down by a liver enzyme called CYP3A4. Herbal supplements like St. John's Wort are known enzyme inducers that can speed up this process, which may lead to lower concentrations of the medicine and a lessened therapeutic effect.

---

Q: Is Berest a new drug, or has it been around for a while?

The active ingredient in Berest, alprazolam, is not a new compound. It was first approved by the U.S. Food and Drug Administration (FDA) in the 1980s.

---

Q: Does Berest cause stomach upset or nausea?

Official safety data lists vomiting and diarrhea as frequent adverse reactions. Less frequent adverse reactions include dyspepsia (or indigestion) and abdominal pain.

---

Q: What happens if I accidentally take two doses of Berest?

Taking more than the amount prescribed increases the risk of an overdose. According to official safety information, signs of overdose include severe central nervous system (CNS) depression, such as pronounced drowsiness, confusion, and loss of consciousness. In this event, it is important that medical assistance be accessed right away.

---

Q: Is there a generic version of Berest available?

Yes, the FDA's approved drug product information confirms that generic versions of the tablet formulations containing the active ingredient, alprazolam, have been approved for use.

---

Q: Can Berest cause skin reactions or rashes?

Some severe skin reactions, such as blistering, peeling, or red skin lesions, have been documented in association with this medicine. These types of reactions are not common, but are noted in regulatory-linked documents.

---

Q: What is the typical time frame for seeing a benefit from Berest?

In the controlled clinical trials for panic disorder, benefits were typically established within 4 to 10 weeks of beginning treatment. However, the time required to see a benefit can vary for each individual.

---

Q: Does Berest interact with grapefruit juice?

Yes, official regulatory documents and patient-facing materials advise avoiding grapefruit and grapefruit juice. This is because grapefruit can strongly inhibit a key liver enzyme that breaks down the medicine, potentially leading to dangerously high concentrations in the body.

Official Storage and Disposal Requirements

Area	Requirement
Storage Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environment	Keep the medicine in its original, tightly closed container and protect it from direct light, heat, and moisture. The tablets must be kept from freezing.
Child Safety	Due to its classification as a controlled substance, Berest must be stored locked up and kept strictly out of the reach of children.
Disposal	Do not keep outdated or unused medicine. The preferred method for disposal is through a community drug take-back program. If no take-back option is available, unused tablets may be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash. This medicine must not be flushed down the toilet or sink.